/

Empresas

Sy

No verificado

Synnovation Therapeutics

Sobre qué escribimos

BiotecnologíaFarmacéuticaIndustriaMedicina - VariosSalud

3 Comunicados de prensa

Ver todos los comunicados de prensa

14/10/2025

Biotecnología

Salud

Farmacéutica

Medicina - Varios

Oncología

Mercado laboral

Eventos

Ferias y Congresos

Industria

Synnovation to Present SNV1521 (PARP1) Phase 1 Study Results at the European Medical Oncology (ESMO) Congress 2025 and Announces Clinical Collaboration with DualityBio to Evaluate the Combination of SNV1521 with Duality’s HER3 ADC, DB-1310

Fuente

Synnovation Therapeutics

Editor

1.00

0

08/05/2025

Mercado laboral

Farmacéutica

Salud

Medicina - Varios

Synnovation Therapeutics Announces the Appointment of Rafael G. Amado, M.D., to Its Board of Directors

Fuente

Synnovation Therapeutics

Editor

1.00

0

24/02/2025

Biotecnología

Salud

Farmacéutica

Medicina - Varios

Oncología

Industria

Synnovation Therapeutics Announces Second Program to Enter the Clinic: First Patient Dosed in Phase I Trial with SNV4818, a Potential Best-In-Class Pan-Mutant-Selective PI3Kα Inhibitor for the Treatment of Solid Tumors

Fuente

Synnovation Therapeutics

Editor

1.00

0

Seguidores

0

Compatibilidad

0